Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI factory in life sciences, and FDA clears Consano Bio's IND for a non-opioid biologic targeting chronic sciatica.

In a conversation with Pharmaceutical Executive, Invivyd chief scientific officer Robert Allen described how the company's Invymab platform pairs viral surveillance and predictive modeling with antibody engineering to anticipate viral evolution rather than react to it. The platform continuously generates new monoclonal antibody candidates and maps mutational escape routes to help predict which variants are likely to dominate before they emerge. Allen also discussed VYD2311, a candidate positioned as a scalable prophylactic alternative or complement to vaccination against Covid-19, particularly for patients affected by vaccine hesitancy. Invivyd is applying the same underlying platform in parallel across Covid-19, RSV, and measles programs.

Bristol Myers Squibb is expanding its AI computing infrastructure with an Nvidia DGX SuperPOD featuring Vera Rubin NVL72 systems, which the company says will be the most powerful, energy-efficient AI infrastructure in life sciences. The new architecture delivers up to ten times greater performance per megawatt than its predecessor, supporting research across oncology, hematology, cardiovascular disease, immunology, and neuroscience. BMS said AI agents are already automating target identification and validation, saving scientists weeks of manual work, while its "Predict First" methodology now shapes experimental design for every small molecule program. The company frames the effort as a hybrid intelligence model, pairing AI execution with human judgment on interpretation and direction.

FDA has cleared Consano Bio's investigational new drug application for C-1101, clearing the way for the company's Phase I trial in chronic sciatica to expand to U.S. sites. C-1101 is a platelet-derived biologic delivered via a single epidural injection, designed to modulate inflammation and stimulate cellular repair at the site of nerve injury. The therapy is intended as a non-opioid alternative in a condition that currently has no approved pharmaceutical treatment despite costing the U.S. healthcare system an estimated $135 billion annually. Dosing has already begun in Australia, and Consano expects to begin treating U.S. patients within the coming months.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.